SCHEMBL2816376

SCHEMBL2816376

CC(C)Oc1ccc(C(=O)O)nc1Cl

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KMO O15229 2/20 0.49
KDM4E B2RXH2 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
XDH P47989 2/20 0.45
ALOX15 P16050 1/20 0.42
TSHR P16473 1/20 0.42
ACMSD Q8TDX5 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
MCL1 Q07820 2/20 0.42
ALDH1A1 P00352 1/20 0.41
RORC P51449 1/20 0.41
IRAK4 Q9NWZ3 2/20 0.40
PTGER1 P34995 1/20 0.40
KMT2A Q03164 1/20 0.40
S1PR1 P21453 1/20 0.39
CTSA P10619 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16173478 0.87 RORC (0.44) KMOTSHRALDH1A1RORCIRAK4
SCHEMBL2811357 0.84 CYP1A2 (0.44) KMOKDM4EL3MBTL1TSHRALDH1A1
SCHEMBL2812232 0.81 P2RX7 (0.46) KMOMCL1ALDH1A1RORCIRAK4
SCHEMBL11894355 0.81 KDM4E (0.67) KMOKDM4EL3MBTL1XDHALOX15
SCHEMBL29375401 0.81 KDM4E (0.66) KMOKDM4EL3MBTL1ALOX15TSHR
SCHEMBL1759891 0.81 KDM4E (0.66) KMOKDM4EL3MBTL1ALOX15TSHR
Hydrochloric Acid SCHEMBL7225758 0.79 KDM4E (0.64) KMOKDM4EL3MBTL1ALOX15TSHR
SCHEMBL11894473 0.79 KDM4E (0.54) KMOKDM4EL3MBTL1XDHALOX15
SCHEMBL16741093 0.74 KDM4E (0.49) KMOKDM4EL3MBTL1XDHPTGER1
SCHEMBL2306249 0.73 KMO (0.49) KMOKDM4EL3MBTL1ALOX15TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103403004-A Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels VERTEX PHARMA 2013-11-20 CN disclosed
WO-2010117662-A1 MODULATORS OF S1P AND METHODS OF MAKING AND USING EXELIXIS, INC. (US) 2010-10-14 WO disclosed
US-20100249071-A1 Modulators of S1P and Methods of Making And Using EXELIXIS, INC. (US) 2010-09-30 US disclosed
US-20100249071-A1 Modulators of S1P and Methods of Making And Using EXELIXIS, INC. (US) 2010-09-30 US disclosed
US-20100249071-A1 Modulators of S1P and Methods of Making And Using EXELIXIS, INC. (US) 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249071-A1 Modulators of S1P and Methods of Making And Using S1PR5, S1PR1, S1PR2 KMO 1138/4885KDM4E 1216/4885L3MBTL1 3241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.